YES1 Antibody
- Known as:
- YES1 Antibody
- Catalog number:
- ENZ-007525-M03
- Product Quantity:
- 0.1mg
- Category:
- Antibodies
- Supplier:
- Zyagen
- Gene target:
- YES1 Antibody
Related genes to: YES1 Antibody
- Gene:
- YES1 NIH gene
- Name:
- YES proto-oncogene 1, Src family tyrosine kinase
- Previous symbol:
- -
- Synonyms:
- Yes, c-yes, HsT441
- Chromosome:
- 18p11.32
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2016-10-05
Related products to: YES1 Antibody
Related articles to: YES1 Antibody
- Preserving adult hippocampal neurogenesis alleviates cognitive deficits in Alzheimer's disease (AD), yet how biophysical alterations in such as stiffness in the neurogenic niche regulate neurogenesis remains unclear. - Source: PubMed
Sun WeiqiYang BiyuZheng HanyuanWang QiShi YajiaoWang GandigYin WangWang HuiQi XuetaoYao YunWang JiaxinCui ShuangCui KunMao JianXia YiyuanDeng JianwenZhao SiyuanWang ZhihaoLiu FengyuYi MingDing JiuyangLe WeidongLi XinyanYuan JunliangWan YouZheng Jie - Hepatocellular carcinoma (HCC) has a poor prognosis, necessitating therapeutic targets, while the role of ubiquitin-specific protease 3 (USP3) in HCC remains unclear. This study aimed to elucidate the function of the deubiquitinating enzyme USP3 in HCC. USP3 was found to be highly expressed in HCC tissues and associated with poor prognosis. Functional assays in cells and animal models confirmed that USP3 promotes tumor proliferation, migration, and invasion. Mechanistically, USP3 directly binds to yes1-associated transcriptional regulator (YAP) via its ubiquitin C-terminal hydrolase (UCH) domain interacting with YAP's WW domain, removing K11/K48-linked polyubiquitin chains to stabilize the YAP protein. The screening results showed that the pan-deubiquitinating enzyme (DUB) inhibitor PR-619 could inhibit USP3 activity to a certain extent and significantly suppress the growth and metastasis of HCC. Notably, YAP overexpression partially reversed this inhibition. In conclusion, USP3 drives HCC progression by deubiquitinating and stabilizing YAP, and PR-619 demonstrates anti-tumor efficacy, establishing USP3 as a potential therapeutic target for HCC. - Source: PubMed
Publication date: 2026/08/22
Peng YuanhaoNie HuiLi XuanxuanTao YongguangZhou Yangying - The ovarian cancer immunoreactive antigen domain-containing protein 1 (OCIAD1) is a mitochondrial protein implicated in mitochondrial morphology, energy metabolism, and differentiation. Although understudied, recent studies position it as a critical player in carcinogenesis and neurodegenerative disorders, making it a potentially druggable node in cellular signaling networks. However, the phosphoregulatory networks and the upstream kinases governing OCIAD1 remain unknown. - Source: PubMed
Publication date: 2026/07/23
Fahma AmalSubair SuhailLubaba FathimathulGopalakrishnan Athira PerunellyShivamurthy Prathik BasthikoppaRaju Rajesh - Ivermectin suppresses tumor growth in various cancers. However, the mechanism of action in cancer remains unclear. This study aimed to investigate the anticancer activity of ivermectin against gastric cancer cell lines and patient-derived organoids. - Source: PubMed
Publication date: 2026/04/26
Lee SunwoongJung Deuk KjuKim DohyangLim Hee JeongNam Su Youn - Sinonasal squamous cell carcinoma (SNSCC) is a rare malignancy arising de novo or from inverted papilloma (IP), a benign neoplasm with malignant potential. The molecular drivers of IP-associated SNSCC (IP-SNSCC) remain poorly defined, and no effective therapies are available. Progress is hindered by limited preclinical studies and prospective clinical investigations. We performed multi-omic profiling, including whole-exome, RNA, and mitochondrial DNA sequencing (mtDNA-Seq), of matched normal sinonasal epithelium, IP, and SNSCC samples from 11 patients. Analyses revealed a stepwise transcriptional continuum across histological stages, marked by progressive activation of the cell cycle, extracellular matrix remodeling, and metabolic pathways, with suppression of immune and apoptotic signaling. Shared genomic aberrations were detected in only a subset of paired IP and SNSCC specimens, whereas mtDNA-Seq revealed no overlapping mutations, indicating divergent mitochondrial evolution even in clonally related lesions. Given the need for targeted therapies, we applied PandaOmics, an AI-driven target discovery platform, to genes progressively upregulated during IP-SNSCC development. We first prioritized targets with FDA-approved inhibitors, identifying CDK6, EGFR, HDAC, and SRC/YES1 as repurposing candidates, and nominated AURKA, PLK4, TTK, and CDK1/7 as druggable preclinical targets. Together, this study defines the molecular basis of IP-SNSCC and provides a foundation for future translational investigation. - Source: PubMed
Publication date: 2026/07/10
Singh AlkaKorzinkin MichaelSarkisova ViktoriaVergasova EkaterinaRosenberg Ari JSuresh KarthikMishra VasudhaMiao YuxuanShen LeSmolik JuliaVeviorskiy AlexanderPun Frank WCheng XiangyingWing ClaudiaPinto JayantLow Christopher MLingen Mark WRooper LisaPearson Alexander TVokes Everett ELiu XuanyaoLondon NyallZhavoronkov AlexAgrawal NishantIzumchenko Evgeny